Literature DB >> 23928732

Mst1 overexpression inhibited the growth of human non-small cell lung cancer in vitro and in vivo.

C M Xu1, W W Liu, C J Liu, C Wen, H F Lu, F S Wan.   

Abstract

Mammalian STE20-like kinase 1 (Mst1) ubiquitously encodes serine threonine kinase, which is a 59-kDa class II GC kinase that shares 76% identity in amino-acid sequence with MST2, and is the closest mammalian homolog of Drosophila Hippo protein kinase, a major inhibitor of cell proliferation in Drosophila. Recent studies have shown that Mst1 and Mst2 perform tumor-suppressor function in a redundant manner and were originally identified as pro-apoptotic cytoplasmic kinases important for controlling cell growth, proliferation, apoptosis and organ size. We used recombinant eukaryotic expression vector containing human wild-type Mst1 gene to transfect human non-small cell lung cancer (NSCLC) A549 cells in vitro and in vivo. The results showed that Mst1 overexpression inhibited cell proliferation and induced apoptosis of A549 cells, promoted Yes-associated protein (YAP) (Ser127) phosphorylation and downregulated the transcriptional level of Cystein-rich protein connective tissue growth factor (CTGF), amphiregulin (AREG) and Survivin. In human NSCLC-cell-A549-xenograft models, Mst1 gene or cisplatin alone suppressed the growth of tumors and increased the cytoplasm-positive expression levels of YAP and Phospho-YAP (Ser127) proteins; however, their combination had the strongest anticancer effects. Overall, Mst1 has an important role in inhibiting the growth of NSCLC in vitro and in vivo; its antiproliferative effect is associated with induction of apoptosis through promotion of the cytoplasmic localization and phosphorylation of YAP protein at Ser127 site, indicating that Mst1 may be developed as a promising therapeutic target for NSCLC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23928732     DOI: 10.1038/cgt.2013.40

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  28 in total

1.  Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest.

Authors:  Richard J Mills; Drew M Titmarsh; Xaver Koenig; Benjamin L Parker; James G Ryall; Gregory A Quaife-Ryan; Holly K Voges; Mark P Hodson; Charles Ferguson; Lauren Drowley; Alleyn T Plowright; Elise J Needham; Qing-Dong Wang; Paul Gregorevic; Mei Xin; Walter G Thomas; Robert G Parton; Lars K Nielsen; Bradley S Launikonis; David E James; David A Elliott; Enzo R Porrello; James E Hudson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-15       Impact factor: 11.205

2.  Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer.

Authors:  Kanchan Singh; Melissa A Pruski; Kishore Polireddy; Neal C Jones; Qingzheng Chen; Jun Yao; Wasim A Dar; Florencia McAllister; Cynthia Ju; Holger K Eltzschig; Mamoun Younes; Cesar Moran; Harry Karmouty-Quintana; Haoqiang Ying; Jennifer M Bailey
Journal:  Oncogene       Date:  2019-09-30       Impact factor: 9.867

3.  Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.

Authors:  Y-L Hsu; J-Y Hung; S-H Chou; M-S Huang; M-J Tsai; Y-S Lin; S-Y Chiang; Y-W Ho; C-Y Wu; P-L Kuo
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

Review 4.  Disease implications of the Hippo/YAP pathway.

Authors:  Steven W Plouffe; Audrey W Hong; Kun-Liang Guan
Journal:  Trends Mol Med       Date:  2015-02-18       Impact factor: 11.951

5.  YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer.

Authors:  Gamze Kuser-Abali; Ahmet Alptekin; Michael Lewis; Isla P Garraway; Bekir Cinar
Journal:  Nat Commun       Date:  2015-09-01       Impact factor: 14.919

Review 6.  The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Authors:  Xiao-Lan Liu; Rui Zuo; Wen-Bin Ou
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

7.  Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.

Authors:  Bin You; Yi-Lin Yang; Zhidong Xu; Yuyuan Dai; Shu Liu; Jian-Hua Mao; Osamu Tetsu; Hui Li; David M Jablons; Liang You
Journal:  Oncotarget       Date:  2015-02-28

8.  ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRA.

Authors:  Katrin Schelleckes; Boris Schmitz; Malte Lenders; Mirja Mewes; Stefan-Martin Brand; Eva Brand
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379

9.  Expression of hippo pathway in colorectal cancer.

Authors:  Kun Liang; Guangxi Zhou; Qi Zhang; Jing Li; Cuiping Zhang
Journal:  Saudi J Gastroenterol       Date:  2014 May-Jun       Impact factor: 2.485

Review 10.  The role of the Hippo pathway in human disease and tumorigenesis.

Authors:  Daniel A Barron; Jacob D Kagey
Journal:  Clin Transl Med       Date:  2014-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.